A Novel Phosphodiesterase Inhibitor, T-440: Possible Management of Eosinophilic Inflammation by Down-Regulation of lnterleukin-5 Production

1 January 1996

journal article
Published by S. Karger AG in International Archives of Allergy and Immunology

Vol. 111 (1) , 16-18
https://doi.org/10.1159/000237407

Abstract

The effect of T-440, a selective type IV phosphodiesterase (PDEIV) inhibitor, on interleukin (IL)-5 production by peripheral blood mononuclear cells (PBMCs) of atopic asthmatic subjects was investigated. PBMCs produced IL-5 following challenge with specific allergen in vitro. T-440 suppressed allergen-induced IL-5 production significantly at a concentration of 1 μg/ml. T-440 inhibited cyclic AMP-phosphodiesterase (PDE) activity in a concentration-dependent manner and raised the intracellular cyclic AMP level of PBMCs significantly. Dibutyryl cyclic AMP suppressed IL-5 production by PBMCs in a similar way to T-440, suggesting that the increase of intracellular cyclic AMP caused by T-440 reduces IL-5 production. T-440 may be an effective agent to treat atopic diseases associated with eosinophilic inflammation, e.g. asthma and atopic dermatitis.

Keywords

This publication has 0 references indexed in Scilit: